Drug Review: Rezafungin

PTB Reports, 2024, 10, 4, 118-119.
DOI: 10.71092/PTB.2024.10.24
Published: December 2024
Type: Drug Review
Authors: Juman Alsaab

 

Author(s) affiliations:

Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Regulations: They have been registered in the following countries: the United States of America (USA) and the European Union (E.U.).
General Information:
Registered Company: Melinta Therapeutics.
Regulatory Status: R.X.
Mechanism of Action: inhibits the 1,3-beta-D-glucan synthase enzyme complex in fungal cell walls.
Read More…


Leave a Reply

Your email address will not be published. Required fields are marked *